

## Optimization of antibiotic prophylaxis: computerized decision support system of the University Hospital Center of Charleroi

BAPCOC WORKSHOP 2 OCTOBER 2019

# Change in Antibiotic prophylaxis practices 2016 -2019







Presentation of the tool

Results

Conclusion and Perspectives





i. PARDO 2 OCTOBER 2019

Presentation of the tool

Results

Conclusion and Perspectives

Marie Curie 2016-2017

#### **Pre-test Analysis**

Antibiotic prophylaxis practices between January 11, 2016 and April 22, 2016



#### **Inclusion criteria**

Patients > 18 years old

Patients who had one of the following 5 interventions: total hip prosthesis, coronary artery bypass grafting, colorectal surgery, transurethral resection of the prostate and endoscopic retrograde cholangiopancreatography

#### **Exclusion criteria**

Patients < 18 years old

Patients with a documented infection at the time of the intervention

### Risk factors of non-compliance in the pre-test group? Retrospective observational transversal study

- → using a multivariate statistical analysis (Logistic regression models and Wald Tests)
- → with Odds Ratios (ORs) determination for the relationships between each independent variable and the outcome variables :

#### **INDEPENDENT VARIABLES**

- Age
- Obesity
- •Gender
- •IgE Mediated Penicillin (or Ciprofloxacin) Allergy
- Multidrug-resistant organisms
- American Society of Anaesthesiologists Score2
- •Length of Preoperative Stay
- •Type of Intervention
- •Surgeon or Gastroenterologist
- Anesthetist
- Presence of a nurse anesthetist during the intervention
- Duration of the intervention
- Blood loss during surgery ≥ 1,5L

#### **OUTCOME VARIABLES**

- Compliance in terms of the items:
- Indication
- Molecule(s) (1st administration)
- Dose(s) (1st administration)
- Route of administration (1st administration)
- Time of administration (1st administration)
- Number of administration(s)
- Duration of prophylaxis

Marie Curie 2016-2017

#### **Pre-test Analysis Antibiotic prophylaxis practices**

between January 11, 2016 and April 22, 2016

Risk factors of non-compliance in the pre-test group?

#### **Retrospective observational transversal study**

- → using a multivariate statistical analysis (Logistic regression models and Wald Tests)
- → with Odds Ratios (ORs) determination for the relationships between each independent variable and the outcome variables

| Risk factor of | f non compliance in | terms of Indication | (Overall significan | ce of the model: I | P=0,0001) |
|----------------|---------------------|---------------------|---------------------|--------------------|-----------|
|                |                     |                     |                     |                    |           |

| Characteristics                                    | Z-test | P      | OR                        |
|--|--------|--------|---------------------------|
|  |        |        | (95% IC)                  |
| IgE Mediated Penicillin (or Ciprofloxacin) Allergy | -2,383 | 0,0172 | 0,0345<br>(0,0022-0,5502) |
| Preoperative length of stay (days)                 | 2,7    | 0,0069 | 27,5803                   |
|  |        |        | (2,4824-306,4210)         |

Risk factor of non compliance in terms of Molecule (Overall significance of the model : P = 5.96E-10)

| Table record of non-compliance in terms of records (o versus significance of the model of 2,502 10) |        |        |                 |  |  |
|---|--------|--------|-----------------|--|--|
| Characteristics   | Z-test | Р      | OR              |  |  |
|   |        |        | (95% IC)        |  |  |
| IgE Mediated Penicillin (or Ciprofloxacin) Allergy  | -2,012 | 0,0442 | 0,1282          |  |  |
| 0   |        |        | (0,0173-0,9481) |  |  |
| Colorectal surgery  | -3,233 | 0,0012 | 0,0187          |  |  |
| <u> </u>  |        |        | (0,0017-0,2086) |  |  |
| Transurethral resection of the prostate   | -3,07  | 0,021  | 0,0933          |  |  |
| · ·   |        |        | (0,0205-0,4243) |  |  |
| Duration of the intervention (HH:mm:ss)   | 2,316  | 0,0206 | 3,3669          |  |  |
|   |        |        | (1,2051-9,4068) |  |  |

#### Risk factor of non compliance in terms of Dose (Overall significance of the model : P = 6.25E-08)

| Table 14 con compliance in terms of 2 obe (5 verail significance of the model 1 object of) |               |        |                 |   |  |  |
|--|---------------|--------|-----------------|---|--|--|
| Characteristics  | <b>Z-test</b> | P      | OR              | ] |  |  |
|  |               |        | (95% IC)        |   |  |  |
| Colorectal surgery   | -3,321        | 0,0009 | 0,0623          | k |  |  |
|  |               |        | (0,0194-0,2007) |   |  |  |
| Transurethral resection of the prostate  | -2,824        | 0,0047 | 0,1614          |   |  |  |
| ·  |               |        | (0,0455-0,5724) |   |  |  |
| Duration of the intervention (HH:mm:ss)  | 2,412         | 0,0159 | 2,1697          | L |  |  |
|  |               |        | (1,1563-4,0713) |   |  |  |

Presentation of the tool

Results

**Conclusion and Perspectives** 

Marie Curie 2016-2017

Pre-test Analysis
Antibiotic prophylaxis practices
between January 11, 2016 and April 22, 2016

#### Risk factors of non-compliance in the pre-test group?

#### Retrospective observational transversal study

- → using a multivariate statistical analysis (Logistic regression models and Wald Tests)
- → with Odds Ratios (ORs) determination for the relationships between each independent variable and the outcome variables

**Risk factor of non compliance in terms of Route of administration** (Overall significance of the model: P=9,03E-09)

| Misk factor of non-comphanice in terms of Route of authinistration (Overall significance of | i tile illoue | 7 . 1 - 2,03L 02) |                 |
|---|---------------|-------------------|-----------------|
| Characteristics   | Z-test        | Р                 | OR              |
|   |               |                   | (95% IC)        |
| Transurethral resection of the prostate   | -4,44         | 2,37E-09          | 0,0393          |
|   |               |                   | (0,0094-0,1641) |
| Anesthetist 3   | -2,377        | 1,74E-02          | 0,0761          |
|   |               |                   | (0,0091-0,6365) |
| Anesthetist 4   | -2,074        | 0,0381            | 0,0815          |
|   |               |                   | (0,0076-0,8713) |

(i)Some anesthetists have also emerged as risk factors of non-compliance. However, we cannot exclude a dependence between independent variables (cf. link between practitioners and certain types of intervention).

Risk factor of non compliance in terms of Time of administration (Overall significance of the model : P = 5.02E-12)

| Characteristics                         | Z-test | Р        | OR<br>(95% IC)            |
|---|--------|----------|---------------------------|
| Transurethral resection of the prostate | -6,093 | 1,33E-09 | 0,0293<br>(0,0094-0,0918) |

#### Risk factor of non compliance in terms of Duration of prophylaxis (Overall significance of the model : P = 7,91E-08)

| Characteristics      | Z-test | P        | OR<br>(95% IC)            |
|----------------------|--------|----------|---------------------------|
| Total hip prosthesis | -5,002 | 5,66E-07 | 0,0602<br>(0,0200-0,1811) |

Presentation of the tool

Results

Conclusion and Perspectives

Marie Curie 2016-2017

Pre-test Analysis
Antibiotic prophylaxis practices
between January 11, 2016 and April 22, 2016

### Risk factors of non-compliance in the pre-test group? Retrospective observational transversal study

- → using a multivariate statistical analysis (Logistic regression models and Wald Tests)
- → with Odds Ratios (ORs) determination for the relationships between each independent variable and the outcome variables :

- $\rightarrow$ These findings are consistent with those described in the literature that also revealed as risk factors of non-compliance: allergy to  $\beta$ -lactams and certain types of surgery as urological surgery and digestive surgery\*.
- → Lack of education and incomplete professional rules were probably the main barriers associated with the risk factors identified in the pretest group.
- → The results of this observational study indicated that it was necessary to implement improvement actions of practices.

PARDO 2 OCTOBER 2019

Marie Curie 2016-2017

Presentation of the tool

Results

Zhang H-X, Li X, Huo H-Q, Liang P, Zhang J-P, Ge W-H. PLoS

ONE. 2014;9(2):e88971

Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM. J Clin Phar Ther. 2015;40(4):404-8. Conclusion and Perspectives



Multidisciplinary team

**Local Guidelines** 

**Audits** 

Implementation of Guidelines

Pharmacist Interventions

Nominal delivery

of antibiotic kits

Zhou L, Ma J, Gao J, Chen S, Bao J. Medicine (Baltimore).

Gindre S, Carles M, Aknouch N, Jambou P, Dellamonica P, Raucoules-Aimé M, et al. Annales Françaises d'Anesthésie et de Réanimation. 2004;23(2):116-23.

2016;95(9):e2753.

Prado MAMB, Lima MPJS, Gomes IdRH, Bergsten-Mendes G. Am J Infect Control. 2002;30(1):49-56.

Nair BG, Newman S-F, Peterson GN, Schwid HA. SURGICAL INFECTIONS. 2011;12(1):57-63.

Nair BG, Newman S-F, Peterson GN, Wu W-Y, Schwid HA. Anesth Analg. 2010;111(5):1293-300.

Wax DB, Beilin Y, Levin M, Chadha N, Krol M, Reich DL. Anesth Analg. 2007;104(6):1462-6.

Fayolle-Pivot L, Weyb P-F, Petitjeans F, Puidupin M, Allaouchiche B, Escarment J. Annales Françaises d'Anesthésie et de Réanimation. 2013;32:241–5. Active pharmacist interventions to prescribers

Audit feedback

Educational session & Diffusion of Guidelines

Littérature

Littérature

Informatic tool

Prescribing aid

Reminder

A. PARDO 2 OCTOBER 2019

)

Marie Curie 2016-2017

Presentation of the tool

Results

Conclusion and Perspectives

#### <u>Combination of persuasive interventions</u>:

Strategy tested during 15 weeks (between January 9, 2017 and April 21, 2017) at CHU de Charleroi – Marie Curie

#### **Inclusion criteria**

Patients > 18 years old

Patients who had one of the following 5 interventions: total hip prosthesis, coronary artery bypass grafting, colorectal surgery, transurethral resection of the prostate and endoscopic retrograde cholangiopancreatography

#### **Exclusion criteria**

Patients < 18 years old

Patients with a documented infection at the time of the intervention

Nair BG, Newman S-F, Peterson GN, Wu W-Y, Schwid HA. Anesth Analg. 2010;111(5):1293-300.

Wax DB, Beilin Y, Levin M, Chadha N, Krol M, Reich DL. Anesth Analg. 2007;104(6):1462-6.

Fayolle-Pivot L, Weyb P-F, Petitjeans F, Puidupin M, Allaouchiche B, Escarment J. Annales Françaises d'Anesthésie et de Réanimation. 2013;32:241–5.

Multidisciplinary team

**Local Guidelines** 

Audits

Implementation of Guidelines

Nominal delivery of antibiotic kits

**Pharmacist** 

Interventions

Informatic tool

A. PARDO 2 OCTOBER 2019

10

Presentation of the tool

Results

Conclusion and Perspectives

Marie Curie 2016-2017

#### **Pre-test Analysis**

Antibiotic prophylaxis practices between January 11, 2016 and April 22, 2016



Combination of persuasive interventions From December 2016 to April 2017

#### **Post-Test Analysis**

Antibiotic prophylaxis practices between January 9, 2017 and April 21, 2017





Presentation of the tool

Results

Conclusion and Perspectives

Tested Strategy (December 2016-April 2017)



Encoding of an antibiotic prophylaxis recommendation based on patient parameters

→accessible in patients' computerized records



Pre-operative delivery of nominative kits containing the antibiotics with a recommendation paper



**Operating room / Care Unit** 









Marie Curie 2016-2017

Monocentric quasi-experimental study with a pre-test — Post-test evaluation

**Pre-test group Analysis Antibiotic prophylaxis practices** between January 11, 2016 and April 22, 2016

#### Test phase **Combination of persuasive interventions** From December 2016 to April 2017

**Test group Analysis Antibiotic prophylaxis practices** between January 9, 2017 and April 21, 2017



#### **Inclusion criteria**

Patients > 18 years old

Patients who had one of the following 5 interventions: endoscopic retrograde cholangiopancreatography

1) Similarity between the pre-test group and the test group

variables (number of patients per type of intervention, number of long duration interventions (> 3 hours), number of allergic patients)

x2 test for categorical

• Student's t-test for the age variable

Characteristics total hip prosthesis, coronary artery bypass grafting, colorectal surgery, transurethral resection of the prostate and Number of Interventions, n Age (yr), mean±SD 66,32 ± Transurethral resection of the prostate, n (%) 26 (2 **Exclusion criteria** Coronary artery bypass grafting, n (%) 38 (29 Colorectal surgery, n (%) 17 (13 Patients < 18 years old Total hip prosthesis, n (%) 30 (23 the prostate) Patients with a documented infection at the time of the Endoscopic retrograde cholangiopancreatography, n (%) 19 (14 intervention Duration of intervention > 3h, n (%) 48 (36 IgE Mediated Penicillin (or Ciprofloxacin) Allergy, n (%) 0,86<sup>NS</sup> 6 (4,62) 6 (5,08) 12 (4,84)

al characteristics of patients in the pre-test group and the test group larity between the two groups in terms of clinical and demographic characteristics except for the number of transurethral resection of

Comparing the pretest group with the test group: NS, not significant; \*significant



Presentation of the tool

Results

Conclusion and Perspectives

Marie Curie 2016-2017

Monocentric quasi-experimental study with a pre-test — Post-test evaluation

**Pre-test Analysis Antibiotic prophylaxis practices** between January 11, 2016 and April 22, 2016

Test phase **Combination of persuasive interventions** From December 2016 to April 2017

**Post-Test Analysis Antibiotic prophylaxis practices** between January 9, 2017 and April 21, 2017

Impact of the combined intervention strategy on compliance towards prophylactic antibiotic auidelines?

> Difference of compliance between the two groups?

χ2 test comparing the % of compliance between the two groups for each of the 7 items audited



Comparison of antibiotic prophylaxis practices in the pre-test group (n = 130) versus the test group (n = 118)

→ Significant increase in compliance for all items assessed (test group vs. pre-test group) (P < 0.05 for all items assessed)

<sup>a</sup> Comparing the pre-test group with the test group:

\*significant

Advantages-Disadvantages

Presentation of the tool

Results

Conclusion and Perspectives

### **Combination of persuasive interventions From December 2016 to April 2017**

## Advantages of active persuasive strategies\*

- † visibility of antimicrobial stewardship program
- 个 collegial relationships
- ↑ uptake of guidelines by prescribers
- Can be done on less than daily basis if resources are limited
- Provides educational benefit to clinicians
- ↑ quality of practice

## Disadvantages of active persuasive strategies\*

- Success depends on stewardship method
- Typically labor-intensive
- Prescribers reluctant to change

A. PARDO 2 OCTOBER 2019 15

<sup>\*</sup>From Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2016;62(10):e51-e77.

Results

Conclusion and Perspectives

Marie Curie 2017-2018

#### Sustained effect of the strategy implemented?

Analysis of Antibiotic prophylaxis practices
with stewardship actions
between January 9, 2017 and April 21, 2017

Analysis of Antibiotic prophylaxis practices
without stewardship action
between January 8, 2018 and April 20, 2018

Similarity between the 2017 test group versus the 2018 post-test group ?

- χ2 test for categorical variables (number of patients per type of intervention, number of long duration interventions (> 3 hours), number of allergic patients)
- Student's t-test for the age variable

| Characteristics   | Group 2017    | Group 2018    | Total         | <b>P</b> (a)       |
|---|---------------|---------------|---------------|--------------------|
| Number of Interventions, n                                | 118           | 124           | 242           |                    |
| Age (yr), mean±SD   | 68,36 ± 13,75 | 65,78 ± 13,63 | 67,29 ± 13,72 | 0,15 <sup>NS</sup> |
| Transurethral resection of the prostate, n (%)            | 11 (9,32)     | 9 (7,26)      | 20 (8,26)     | 0,56 <sup>NS</sup> |
| Coronary artery bypass grafting, n (%)                    | 34 (28,81)    | 30 (24,19)    | 64 (26,45)    | 0,42 <sup>NS</sup> |
| Colorectal surgery, n (%)                                 | 22 (18,64)    | 19 (15,32)    | 41 (16,94)    | 0,49 <sup>NS</sup> |
| Total hip prosthesis, n (%)                               | 34 (28,81)    | 38 (30,65)    | 72 (29,75)    | 0,76 <sup>NS</sup> |
| Endoscopic retrograde cholangiopancreatography, n (%)     | 17 (14,41)    | 28 (22,58)    | 45 (18,6)     | 0,10 <sup>NS</sup> |
| Duration of intervention > 3h, n (%)                      | 52 (44,07)    | 48 (38,71)    | 100 (41,32)   | 0,40 <sup>NS</sup> |
| IgE Mediated Penicillin (or Ciprofloxacin) Allergy, n (%) | 6 (5,08)      | 11 (8,87)     | 17 (7,02)     | 0,25 <sup>NS</sup> |

#### **Inclusion criteria**

Patients > 18 years old

Patients who had one of the following 5 interventions: total hip prosthesis, coronary artery bypass grafting, colorectal surgery, transurethral resection of the prostate and endoscopic retrograde cholangiopancreatography

#### **Exclusion criteria**

Patients < 18 years old

Patients with a documented infection at the time of the intervention

f clinical

st group

and demographic characteristics

(p> 0.05 for all variables analyzed)

 $^{
m (a)}$  Comparing the test group with the post-test group: NS, not significant; \*significant

A. PARDO 2 OCTOBER 2019

Presentation of the tool

Results

Conclusion and Perspectives


Marie Curie 2017-2018

#### Sustained effect of the strategy implemented?

**Analysis of Antibiotic prophylaxis practices** with stewardship actions between January 9, 2017 and April 21, 2017

**Analysis of Antibiotic prophylaxis practices** without stewardship action between January 8, 2018 and April 20, 2018 Difference of compliance between the two groups?

χ2 test comparing the % of compliance between the two groups for each of the 7 items audited



Comparison of antibiotic prophylaxis practices in the 2017 test group (n = 118) versus the 2018 post-test group (n = 124)

→ Significant decrease in compliance for 4 out of 7 items assessed (test group vs. Post-test group)

(P < 0.05 for 4 items assessed)

0,08909367NS

\*significant

0.0129507\*

0,06405966NS


NS, Not significant

0,26094642NS

0,00087145\*

0,00155704\*

0,0129507\*



Tool presented to the hospital antibiotic group (GGA) on March 20, 2018



#### Tool made available for all the staff members in the Medical Information System of CHU Charleroi:

- at sharepoints of the concerned medical disciplines including anesthesia and all surgical units
- in the Scientific Portal (in Consensus & Recommendations for Clinical Practice)



### How was the tool presented?

#### Via a video broadcast:

- by email on December 20,2018
  - in the Medical Information System of CHU Charleroi on December 21, 2018

#### Results

Marie Curie 2018-2019

Conclusion and Perspectives

**Pre-test group Analysis Antibiotic prophylaxis practices** between January 8, 2018 and April 20, 2018 Diffusion of the computerized decision support system December 20-21, 2018

**Test group Analysis Antibiotic prophylaxis practices** between January 7, 2019 and April 19, 2019

#### **Inclusion criteria**

Patients > 18 years old

Patients who had one of the following 5 interventions: total hip prosthesis, coronary artery bypass grafting, colorectal surgery, transurethral resection of the prostate and endoscopic retrograde cholangiopancreatography

**Similarity** between the 2018 pre-test group versus the 2019 test group

 x2 test for categorical variables (number of patients per type of intervention, number of long duration interventions (> 3 hours), number of allergic patients)

Student's t-test for the age

**Exclusion criteria** 

Patients < 18 years old

ne of the

|   |    | <u>'</u>                                    |            |             |                    |
|---|----|---|------------|-------------|--------------------|
| Age (yr), mean±SD   | 65 | Patients with a documented infection at the |            |             | at the tim         |
| Transurethral resection of the prostate, n (%)            |    | intervention                                |            |             |                    |
| Coronary artery bypass grafting, n (%)                    | 3  | 0 (24,19)                                   | 46 (38,33) | 76 (31,15)  | 0,02*              |
| Colorectal surgery, n (%)                                 | 1  | 9 (15,32)                                   | 12 (10)    | 31 (12,7)   | 0,21 <sup>NS</sup> |
| Total hip prosthesis, n (%)                               | 3  | 8 (30,65)                                   | 31 (25,83) | 69 (28,28)  | 0,40 <sup>NS</sup> |
| Endoscopic retrograde cholangiopancreatography, n (%)     | 2  | 8 (22,58)                                   | 19 (15,83) | 47 (19,26)  | 0,18 <sup>NS</sup> |
| Duration of intervention > 3h, n (%)                      |    | 18 (38,71)                                  | 55 (45,83) | 103 (42,21) | 0,26 <sup>NS</sup> |
| IgE Mediated Penicillin (or Ciprofloxacin) Allergy, n (%) | -  | 11 (8,87)                                   | 6 (5)      | 17 (6,97)   | 0,24 <sup>NS</sup> |
|   |    |   |            |             |                    |

al characteristics of patients in the pre-test group and the test group

variable

→ Similarity between the two groups in terms of clinical and demographic characteristics

(p> 0.05 except for the number of Coronary artery bypass grafting)

**Characteristics** Number of Interventions, n

Comparing the group 2018 with the group 2019: NS, not significant; \*significant

Context Presentation of the tool Conclusion and Perspectives Results Marie Curie 2018-2019 **Test group Analysis Pre-test group Analysis** Diffusion of the computerized decision support **Antibiotic prophylaxis practices Antibiotic prophylaxis practices** system between January 7, 2019 and April 19, 2019 December 20-21, 2018 between January 8, 2018 and April 20, 2018 Impact of the computerized tool on compliance towards prophylactic antibiotic guidelines? Compliant ■ Non-compliant Missing data Difference of χ2 test comparing the compliance % of compliance 21,0 between the between the two two groups? groups for each of the 7 items audited 95.2 84,7 78,2 Comparison of antibiotic prophylaxis practices in the pre-test group (n = 124) versus the test group (n = 120)→ Increase in compliance for 5 out of 7 items 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019 2018 2019

Number of administration(s)

0,67901438<sup>NS</sup>

Duration of prophylaxis

0,21199591<sup>NS</sup>

assessed (non-significant)

Test group vs. Pre-test group P > 0.05 for all items assessed

<sup>a</sup> Comparing the pre-test group with the test group: \*significant NS, Not significant NS, Not significant

0,37222988<sup>NS</sup>

Time of administration

Percentage of interventions

Indication

0,67822624NS

Molecule(s)

0,41589813<sup>NS</sup>

Dose(s)

0,62132075NS

Route of administration

0,80031384NS

**Results** 

Marie Curie 2018-2019

Conclusion and Perspectives

## Informatic tool Advantages

- Integrates the guidelines recently updated and validated by the different actors of antibiotic prophylaxis → specific patient criteria can be integrated
- Recommendations accessible via a computer link (also from outside the hospital →accessible to other hospitals)
- A help with the decision: allows rapid and efficient decision-making adapted to the patient's parameters and in compliance to guidelines
- Stewardship strategy non labor-intensive
- A help to decrease the variability of interindividual prescription and sensitize the teams to the importance of antibiotic prophylaxis

## Informatic tool Disadvantages

- Not connected to the computerized record of the patient → manual encoding required by practitioners
- Absence of reminder recalling the injection of antibiotic in preoperative
- Underused by practitioners

#### Conclusion

It is reported\* that computerized decision support systems appear useful for improving compliance with antibiotic prophylaxis guidelines BUT over time, it is observed a gradual re-increase in the rate of non-compliance of antibiotic prophylaxis → Computer tools are considered useful in a global strategy but without the incorporation of an active interventions, they don't appear sufficient over time to improve the frequency of compliance of practices

Thanks to the combination of stewardship strategies implemented, the Marie Curie Civil Hospital reached the explicit targets of 90% set by the BAPCOC:

Choice of surgical antibiotic prophylaxis according to local guidelines: 92,5% in 2019 vs. 83,1% in 2016 Duration of surgical antibiotic prophylaxis according to local guidelines: 90% in 2019 vs. 82,3% in 2016

#### Perspectives

For anesthesiologists and surgeons: increase communication about the existence of the computerized decision support system

Connect the tool with the computerized records of the patients and integrate a reminder recalling the injection of antibiotic in preoperative


Maintain updated guidelines and updated computer tool

Repeat active interventions and audits

<sup>\*</sup>Fayolle-Pivot L, Weyb P-F, Petitjeans F, Puidupin M, Allaouchiche B, Escarment J. Contribution of information technologies to assess and improve professional practice: Example of management of surgical antibiotic prophylaxis.

A. PARDO 2 OCTOBER 2019

23





Context Presentation of the tool Results Conclusion and Perspectives

## Thank you for your attention